Skip to content

RESPONSE BIOMEDICAL CORP: 10-Q filed 2012-05-08

What RESPONSE BIOMEDICAL CORP reported in its quarterly report filed 2012-05-08 (fiscal Q1 2012): 28 published measures, 57 facts as tagged in accession 0001437749-12-004671.

This filing

Form
10-Q (quarterly report)
Filed
2012-05-08
Fiscal period
fiscal Q1 2012
Accession
0001437749-12-004671 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All RESPONSE BIOMEDICAL CORP filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-03-3119,204,646CAD
At 2011-12-3120,893,266CAD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-03-3119,927,174CAD
At 2011-12-3115,917,543CAD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-03-31-722,528CAD
At 2011-12-314,975,723CAD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-03-314,966,891CAD
At 2011-12-317,354,802CAD
At 2011-03-312,753,495CAD
At 2010-12-314,330,117CAD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-01-01 to 2012-03-31-5,704,330CAD91
2011-01-01 to 2011-03-31-1,523,407CAD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-03-31-2,277,721CAD91
2011-01-01 to 2011-03-31-1,496,265CAD90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-03-31-79,593CAD91
2011-01-01 to 2011-03-31-71,337CAD90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-03-31-30,597CAD91
2011-01-01 to 2011-03-31-9,020CAD90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2012-03-31-112,594,421CAD
At 2011-12-31-106,890,091CAD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2012-01-01 to 2012-03-31129,078,166shares91
2011-01-01 to 2011-03-3138,950,262shares90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-03-318,182,305CAD
At 2011-12-318,433,994CAD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-03-316,079CAD91
2011-01-01 to 2011-03-31131,868CAD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-03-3110,060,330CAD
At 2011-12-3111,497,262CAD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2012-01-01 to 2012-03-31186,986CAD91
2011-01-01 to 2011-03-31199,293CAD90

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-03-3111,835,727CAD
At 2011-12-317,681,981CAD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-03-312,615,621CAD
At 2011-12-313,527,288CAD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2012-03-312,245,079CAD
At 2011-12-311,562,305CAD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-01-01 to 2012-03-311,814,449CAD91
2011-01-01 to 2011-03-311,737,094CAD90

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2012-03-312,398,915CAD
At 2011-12-312,204,443CAD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2012-01-01 to 2012-03-311,269,733CAD91
2011-01-01 to 2011-03-31476,377CAD90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-01-01 to 2012-03-31689,622CAD91
2011-01-01 to 2011-03-31639,946CAD90

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-03-3112,595,640CAD
At 2011-12-3112,589,561CAD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2012-03-31380,834CAD
At 2011-12-31280,968CAD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-01-01 to 2012-03-31870,453CAD91
2011-01-01 to 2011-03-31793,570CAD90

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2012-01-01 to 2012-03-31282,286CAD91
2011-01-01 to 2011-03-31326,619CAD90

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2011-01-01 to 2011-03-3116,929CAD90

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-03-31-682,774CAD91
2011-01-01 to 2011-03-31-342,236CAD90

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-03-31-194,472CAD91
2011-01-01 to 2011-03-31313,219CAD90

Inspect the source

Entity
RESPONSE BIOMEDICAL CORP / CIK 0000806888
Captured
SEC response SHA-256
b41742bfc1aaef19ec515e418525acbab6100f63a8e49faedeae47c5026c8ff8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000806888.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))